Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity.

Wang X, Zhao X, Gu Y, Zhu X, Yin T, Tang Z, Yuan J, Chen W, OuYang R, Yao L, Zhang R, Yuan J, Zhou R, Sun Y, Cui S

Journal of diabetes research26 May 2020Cited by 6 (Europe PMC)

PMID32566685PMCIDPMC7273456DOI10.1155/2020/9783859PepBankPUB-32566685

Summary

In China, most normal BMI (body mass index of ≥18.5 to 2) adults with type 2 diabetes (T2DM) exhibit visceral adiposity. This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity. A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks. Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were quantified by magnetic resonance imaging (MRI) and liver fat content (LFC) by liver proton magnetic resonance spectroscopy (¹H MRS). Each patient's weight, waist circumference, BMI, blood glucose, insulin sensitivity, pancreatic β-cell function, and fibroblast growth factor 21 (FGF-21) levels were measured. Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed. The change in 2 h plasma blood glucose was greater in the exenatide group (P = 0.039). HOMA-IR and MBCI improved significantly after exenatide therapy (P P = 0.045). VAT and LFC decreased in both groups (P P < 0.01). FGF-21 levels declined more in the exenatide group (P r = 0.244, P = 0.043) and after (r = 0.290, P = 0.016) the intervention. The effects of exenatide on glycaemic metabolism, insulin resistance, pancreatic β-cell function, and fat deposition support its administration to normal BMI patients with T2DM and visceral adiposity.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, plasma glucose change was greater with exenatide than Humalog Mix25.
In plain wordsIn normal-BMI patients with type 2 diabetes and visceral fat, two-hour plasma glucose changed more with exenatide than Humalog Mix25.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reported2 h plasma glucose change
Study
n = 81
Comparator
Humalog Mix25
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
The change in 2 h plasma blood glucose was greater in the exenatide group (P = 0.039).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668501
02HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, visceral fat decreased more with exenatide than Humalog Mix25.
In plain wordsIn normal-BMI patients with diabetes and visceral fat, exenatide reduced visceral fat more than Humalog Mix25.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVisceral adipose tissue
Study
n = 81
Comparator
Humalog Mix25
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
VAT and LFC decreased in both groups (P P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668504
03HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, liver fat decreased more with exenatide than Humalog Mix25.
In plain wordsIn normal-BMI patients with diabetes and visceral fat, exenatide reduced liver fat more than Humalog Mix25.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseLiver fat content
Study
n = 81
Comparator
Humalog Mix25
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
VAT and LFC decreased in both groups (P P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668505
04HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, FGF-21 declined more with exenatide than Humalog Mix25.
In plain wordsIn normal-BMI patients with diabetes and visceral fat, FGF-21 fell more with exenatide than Humalog Mix25.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseFGF-21 levels
Study
n = 81
Comparator
Humalog Mix25
Outcome group
Blood biochemical markers · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
FGF-21 levels declined more in the exenatide group (P r = 0.244, P = 0.043) and after (r = 0.290, P = 0.016) the intervention.
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668507
05HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, HOMA-IR improved significantly after exenatide therapy.
In plain wordsIn normal-BMI patients with diabetes and visceral fat, insulin resistance improved after exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHOMA-IR
Study
n = 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
HOMA-IR and MBCI improved significantly after exenatide therapy (P P = 0.045).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668502
06HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, MBCI improved significantly after exenatide therapy.
In plain wordsIn normal-BMI patients with diabetes and visceral fat, the measured beta-cell function index improved after exenatide treatment.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseMBCI
Study
n = 40
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
HOMA-IR and MBCI improved significantly after exenatide therapy (P P = 0.045).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668503
07HumanRandomized controlled trialEfficacy outcome
In normal-BMI patients with diabetes and visceral adiposity, subcutaneous fat decreased only with exenatide therapy.
In plain wordsIn normal-BMI patients with diabetes and visceral fat, fat beneath the skin decreased only in the exenatide group.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseSubcutaneous adipose tissue
Study
n = 40
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
VAT and LFC decreased in both groups (P P < 0.01).
3 context sentences(design, population, supporting numbers)
Summary · context
This study compared the effects of exenatide and humalog Mix25 on normal BMI patients with T2DM and visceral adiposity.
Summary · context
A total of 95 patients were randomized to receive either exenatide or humalog Mix25 treatment for 24 weeks.
Summary · context
Data from 81 patients who completed the study (40 and 41 in the exenatide and humalog Mix25 groups, respectively) were analysed.
Show in the study text Report a problemFND-3256668506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.